Evidence map›Paper›PMID 42700302›Full record

ArticleCardiovascular drugs and therapy2026

From Genetic Prioritization to Therapeutic Validation: Interpreting C4B in Calcific Aortic Valve Stenosis.

Güney Sarıoğlu

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Güney SarıoğluDepartment of Cardiology, Ministry of Health, Battalgazi State Hospital, 44320, Malatya, Turkey. guneysarioglu@outlook.com.ORCID http://orcid.org/0000-0002-1049-1873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Li et al. identified C4B as a potential therapy target for calcific aortic valve stenosis using genetic and histological analyses. However, genetic target prioritization isn't the same as pharmacological validation. Lifelong genetic differences in C4B may not replicate therapeutic inhibition effects, especially given the complex C4A/C4B locus. Increased C4B in calcified valves supports biological relevance but doesn't prove causality. C4B is a promising candidate needing further functional and pharmacological validation.

Identifiers

PMID42700302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.